Cargando…

Clinical Characteristics and Outcomes of Diabetic Ketoacidosis in Patients With Type 2 Diabetes using SGLT2 Inhibitors

BACKGROUND: Sodium glucose cotransporter 2 inhibitors (SGLT2i) use is associated with an increased risk of diabetic ketoacidosis (DKA). OBJECTIVE: This study evaluated and compared the DKA characteristics and outcomes of users and non-users of SGLT2i. METHODS: We retrospectively studied patients wit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Almazrouei, Raya, Afandi, Bachar, AlKindi, Fatima, Govender, Romona, Al-Shamsi, Saif
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9943955/ https://www.ncbi.nlm.nih.gov/pubmed/36844982 http://dx.doi.org/10.1177/11795514231153717

Ejemplares similares

Clinical and biochemical characteristics of diabetic ketoacidosis in adults with type 1 or type 2 diabetes at a tertiary hospital in the United Arab Emirates
por: Almazrouei, Raya, et al.
Publicado: (2022)

Severe Prolonged SGLT2i-induced Euglycemic Diabetic Ketoacidosis Refractory to Standard Therapy and Dialysis: Case Report and Literature Review
por: Almazrouei, Raya, et al.
Publicado: (2022)

Euglycemic Diabetic Ketoacidosis With SGLT-2 Inhibitor
por: Manas, F N U, et al.
Publicado: (2021)

Continuous subcutaneous insulin infusion is associated with a better glycemic control than multiple daily insulin injections without difference in diabetic ketoacidosis and hypoglycemia admissions among Emiratis with Type 1 diabetes
por: Almazrouei, Raya, et al.
Publicado: (2022)

Euglycemic diabetic ketoacidosis in the era of SGLT-2 inhibitors
por: Chow, Erica, et al.
Publicado: (2023)

Rare Coexistence of Acute Intermittent Porphyria With Systemic Lupus Erythematous: Case Report and Literature Review
por: Yusuf, Asmaa, et al.
Publicado: (2023)

Euglycemic Diabetic Ketoacidosis after Discontinuing SGLT2 Inhibitor
por: Alhemeiri, Mohamed, et al.
Publicado: (2022)

Incidence and risk factors of type 2 diabetes mellitus in an overweight and obese population: a long-term retrospective cohort study from a Gulf state
por: Regmi, Dybesh, et al.
Publicado: (2020)

Association of the Genetic Polymorphisms in Transcription Factor 7-Like 2 and Peroxisome Proliferator-Activated Receptors-γ2 with Type 2 Diabetes Mellitus and Its Interaction with Obesity Status in Emirati Population
por: Al-Safar, Habiba, et al.
Publicado: (2015)

SGLT-2 Inhibitors—a Culprit of Diabetic Ketoacidosis Postbariatric Surgery
por: Iqbal, Qasim Zafar, et al.
Publicado: (2020)

A Case of SGLT2 Inhibitor-Induced Euglycemic Diabetic Ketoacidosis
por: Rao, Shiavax J, et al.
Publicado: (2022)

THU387 Euglycemic Diabetic Ketoacidosis And SGLT-2 Inhibitor Use
por: Abrahimi, Nora, et al.
Publicado: (2023)

Mortality and potential years of life lost attributable to non-optimal glycaemic control in men and women with diabetes in the United Arab Emirates: a population-based retrospective cohort study
por: Al-Shamsi, Saif, et al.
Publicado: (2019)

Euglycemic Diabetic Ketoacidosis With COVID-19 Infection in Patients With Type 2 Diabetes Taking SGLT2 Inhibitors
por: Vitale, Rebecca J., et al.
Publicado: (2020)

SGLT2 Inhibitor–Induced Euglycemic Diabetic Ketoacidosis: A Case Report
por: Wang, Katherine M., et al.
Publicado: (2020)

Prolonged glucosuria and relapse of diabetic ketoacidosis related to SGLT2‐inhibitor therapy
por: Westcott, Gregory P., et al.
Publicado: (2020)

SGLT-2 Inhibitor-Associated Euglycemic Diabetic Ketoacidosis: A Case Report and a Literature Review
por: Mahfooz, Rabia Salman, et al.
Publicado: (2022)

Nephrology Consultation for Severe SGLT2 Inhibitor-Induced Ketoacidosis in Type 2 Diabetes: Case Report
por: Nappi, Felice, et al.
Publicado: (2019)

Euglycemic diabetic ketoacidosis induced by SGLT2 inhibitors: possible mechanism and contributing factors
por: Ogawa, Wataru, et al.
Publicado: (2015)

PSUN190 Is Euglycemic Diabetic Ketoacidosis an Underrecognized Risk of SGLT2 Inhibitor Utilization?
por: Block, Romy, et al.
Publicado: (2022)

THU389 Euglycemic Diabetic Ketoacidosis With Prolonged Ketosis Due To SGLT-2 Inhibitor
por: Viera Feliciano, Natalia, et al.
Publicado: (2023)

Validation of the REduction of Atherothrombosis for Continued Health (REACH) prediction model for recurrent cardiovascular disease among United Arab Emirates Nationals
por: Al-Shamsi, Saif, et al.
Publicado: (2020)

Clinical Outcomes of Diabetic Ketoacidosis in Type 2 Diabetes Patients with and without SGLT2 Inhibitor Treatment: A Retrospective Study
por: Nakhleh, Afif, et al.
Publicado: (2023)

Diabetic Euglycemic Ketoacidosis Induced by Oral Antidiabetics Type SGLT2i
por: Velasco de Cos, Guillermo, et al.
Publicado: (2021)

MON-690 Euglycemic Diabetic Ketoacidosis Associated with SGLT-2 Inhibitors- an Under-recognized Diagnosis
por: Chhabra, Sarah, et al.
Publicado: (2020)

Euglycemic diabetic ketoacidosis associated with SGLT2 inhibitors: A systematic review and quantitative analysis
por: Dutta, Siddhartha, et al.
Publicado: (2022)

A Case Report of Euglycemic Diabetic Ketoacidosis in the Setting of Keto Diet and SGLT-2 Inhibitors
por: Marenych, Nadiia, et al.
Publicado: (2021)

Euglycemic Diabetic Ketoacidosis Secondary to SGLT2-inhibitor Use in Combination With a Ketogenic Diet
por: Hester, Joi C, et al.
Publicado: (2021)

COVID-19-associated euglycemic diabetic ketoacidosis in a patient with type 2 diabetes on SGLT2 inhibitor: a case report
por: Batista, Daniel Valente, et al.
Publicado: (2020)

Euglycemic Diabetic Ketoacidosis Post Bariatric Surgery in Type II DM in the Setting of SGLT2-Inhibitor Use
por: Alfares, Khalid, et al.
Publicado: (2021)

ODP183 Diabetic Ketoacidosis Precipitated by Ketogenic Diet and SGLT-2 Inhibitor Use in an Individual with T2DM
por: Mason, Timothy, et al.
Publicado: (2022)

Incidence of cardiovascular disease and its associated risk factors in at-risk men and women in the United Arab Emirates: a 9-year retrospective cohort study
por: Al-Shamsi, Saif, et al.
Publicado: (2019)

External validation and clinical usefulness of three commonly used cardiovascular risk prediction scores in an Emirati population: a retrospective longitudinal cohort study
por: Al-Shamsi, Saif, et al.
Publicado: (2020)

Predictive Value of Creatinine-based Equations of Kidney Function in the Long-term Prognosis in United Arab Emirates Patients
por: Al-Shamsi, Saif, et al.
Publicado: (2021)

Euglycemic Diabetic Ketoacidosis Precipitated by SGLT-2 Inhibitor Use, Pericarditis, and Fasting: A Case Report
por: Mendelsohn, Rebecca A., et al.
Publicado: (2020)

SAT-685 Euglycemic Diabetic Ketoacidosis in T1d: The Era of SGLT-2 Inhibitors and Keto-Diet
por: Castellanos-Diaz, Jessica, et al.
Publicado: (2020)

SGLT2-inhibitors and euglycemic diabetic ketoacidosis in COVID-19 pandemic era: a case report
por: Secinaro, Enzo, et al.
Publicado: (2022)

Risk of diabetic ketoacidosis of SGLT2 inhibitors in patients with type 2 diabetes: a systematic review and network meta-analysis of randomized controlled trials
por: Yang, Shiwen, et al.
Publicado: (2023)

THU380 A Case Of Alpelisib Induced Diabetic Ketoacidosis (Dka) In A Patient With Type 2 Diabetes Mellitus And Rechallenge With SGLT2 Inhibitor
por: Sekar, Vijaykumar, et al.
Publicado: (2023)

Adverse Drug Reaction Profile of SGLT2 Inhibitor-Associated Diabetic Ketosis/Ketoacidosis in Singapore and their Precipitating Factors
por: Limenta, Michael, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_k8v3jc1ss6ipin4vktkv4nmpp1